Compare MAN & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAN | IRON |
|---|---|---|
| Founded | 1948 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 1994 | 2020 |
| Metric | MAN | IRON |
|---|---|---|
| Price | $41.52 | $56.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $52.33 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 991.7K | 567.8K |
| Earning Date | 10-15-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $17,957,100,000.00 | N/A |
| Revenue This Year | $6.49 | N/A |
| Revenue Next Year | $3.49 | N/A |
| P/E Ratio | $34.81 | ★ N/A |
| Revenue Growth | ★ 0.58 | N/A |
| 52 Week Low | $25.15 | $40.00 |
| 52 Week High | $63.88 | $99.50 |
| Indicator | MAN | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 20.20 | 25.35 |
| Support Level | $29.25 | $40.00 |
| Resistance Level | $57.29 | $82.89 |
| Average True Range (ATR) | 2.52 | 2.62 |
| MACD | -1.23 | -0.35 |
| Stochastic Oscillator | 3.93 | 15.32 |
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.